Opinion|Videos|September 13, 2024
Biosimilar Copay Programs
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses biosimilar copay programs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do copay programs impact the adoption of biosimilars for patients, and what role can the pharmacy staff play in educating patients about these programs?
Advertisement
Related to this article
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
A PharmD candidate reflects on the small, evidence-backed daily habits that helped her thrive—not just survive—through pharmacy school's most demanding years.
Understanding local health care priorities is essential to developing meaningful solutions.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5